10-Q: XOMA Royalty Reports Strong H1 Revenue Growth

XOMA Royalty Corporation announced significant revenue growth and improved operating cash flow for the first half of 2025, driven by key milestone achievements and strategic portfolio expansion.

Summary

• Total income and revenues increased to $29.041 million for the six months ended June 30, 2025, up from $12.576 million in the same period of 2024.
• Net income for the six months ended June 30, 2025, was $11.558 million, compared to $7.390 million in the prior year period.
• Net cash provided by operating activities significantly improved to $8.668 million for the six months ended June 30, 2025, from a net cash used of $2.220 million in the same period of 2024.
• The company completed the acquisition of BioInvent's remaining rights to mezagitamab for $20.0 million upfront, with a potential $10.0 million contingent payment upon FDA approval.
• A $5.0 million milestone payment was earned from Rezolute for the last patient dosed in its Phase 3 ersodetug trial.
• A $3.0 million milestone payment was earned from Takeda for the first patient dosed in its Phase 3 mezagitamab trial.
• All five pipeline assets acquired in the Kinnate acquisition were sold to third parties, with potential for up to $270 million in upfront and milestone payments, plus future royalties.
• The company reclassified its Series X Convertible Preferred Stock to temporary equity.
• Repurchased $2.4 million of common stock under its $50.0 million stock repurchase program during the first half of 2025.

Sentiment

Score: 7

Explanation: The company demonstrates strong revenue growth and a significant improvement in operating cash flow, indicating a healthy core business model. Active portfolio expansion through new acquisitions and successful milestone achievements further bolster its future prospects. However, the continued accumulated deficit and substantial cash outflow for investing activities, coupled with reliance on third-party product success and general macroeconomic risks, temper the overall positive sentiment.

Positives

• Significant increase in total income and revenues for the six months ended June 30, 2025, reaching $29.041 million, up from $12.576 million in the prior year.
• Improved net income for the six months ended June 30, 2025, at $11.558 million, compared to $7.390 million in the same period of 2024.
• Strong turnaround in operating cash flow, with $8.668 million provided by operating activities for the six months ended June 30, 2025, a substantial improvement from $2.220 million used in the prior year.
• Successful achievement of a $5.0 million milestone payment from Rezolute for ersodetug's Phase 3 trial.
• Achievement of a $3.0 million milestone payment from Takeda for mezagitamab's Phase 3 trial.
• Successful divestiture of all five pipeline assets from the Kinnate acquisition, with potential for significant future payments up to $270 million plus royalties.
• Reduction in accumulated deficit from $(1,237,057) thousand at December 31, 2024, to $(1,227,892) thousand at June 30, 2025.
• Increased income from purchased receivables under the EIR method, particularly from VABYSMO ($11.575 million for H1 2025) and OJEMDA ($7.240 million for H1 2025).

Negatives

• Net income for the three months ended June 30, 2025, decreased to $9.191 million from $15.985 million in the same period of 2024.
• Significant increase in net cash used in investing activities, rising to $26.674 million for the six months ended June 30, 2025, from $1.350 million in the prior year, primarily due to new acquisitions.
• Continued accumulated deficit of $1.227 billion as of June 30, 2025, despite a reduction from the prior year-end.
• Cash and cash equivalents decreased to $75.060 million at June 30, 2025, from $101.654 million at December 31, 2024.
• Increased net cash used in financing activities to $9.925 million for the six months ended June 30, 2025, from $6.060 million in the prior year.

Risks

• Uncertainty regarding the amount and timing of future milestone or royalty payments, as these are dependent on the achievement of milestones or product sales by third-party licensees.
• Inability to locate suitable assets to acquire or to complete and realize the benefits from future acquisitions.
• Risks inherent in the biotechnology industry and for licensees engaged in the development of new products in a regulated market.
• Potential for product candidates to not receive regulatory approval, preventing manufacturing and marketing by third-party licensees.
• Products or technologies of other companies may render some or all of the company's product candidates noncompetitive or obsolete.
• Fluctuations in operating results and cash flows.
• Sufficiency of capital resources, with potential need to raise additional capital through equity or debt transactions.
• Impact of general macroeconomic and business conditions, including inflationary pressures, economic slowdowns, high interest rates, changes in monetary/trade policies, instability in financial institutions, and geopolitical instability.
• Potential for litigation, arbitration, or other disputes with third parties.
• Reliance on key employees.
• Regulatory and healthcare-related laws and regulations impacting commercialization.

Future Outlook

The company anticipates continued growth in income from purchased receivables, especially from VABYSMO and OJEMDA, based on projected sales estimates. It plans to continue deploying capital for new royalty and acquisition targets, with several recent and pending acquisitions expected to contribute to future revenue streams. The company believes its current financial resources are sufficient to fund planned operations and obligations for at least one year.

Management Comments

• We expect income related to VABYSMO to increase in future periods based on projected sales estimates; however, the increase in income may not be at the same rate as the increase from the 2024 to 2025 periods.
• OJEMDA was launched in the second quarter of 2024, and we expect income from related royalties to increase in future periods based on projections reported by DayOne.
• We do not expect to incur significant Kinnate-related R&D costs in future periods. However, we may incur increased R&D costs associated with our contemplated acquisitions.
• Based on our current cash balance and our planned discretionary spending, such as royalty or other acquisitions, we believe that our current financial resources are sufficient to fund our planned operations, commitments, and contractual obligations for a period of at least one year following the filing date of this Quarterly Report.
• Milestone payments earned in prior periods are not indicative of anticipated milestone payments in future periods.
• We may seek additional capital through our 2018 Common Stock ATM Agreement or our 2021 Series B Preferred Stock ATM Agreement... or through other public or private debt or equity transactions.

Industry Context

XOMA Royalty Corporation operates as a biotech royalty aggregator, a business model focused on acquiring economic rights to future milestone and royalty payments from therapeutic candidates. This strategy allows the company to generate revenue from drug development and commercialization without direct involvement in R&D or sales, leveraging the expertise and funding of its partners. The recent acquisitions and milestone achievements reflect a continued trend of portfolio expansion within the life sciences royalty market, aiming to diversify revenue streams and capitalize on successful drug development by other companies.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Not currently engaged in any legal proceedings that, in the opinion of management, would individually or taken together have a material adverse effect on business, results of operations, financial position or cash flows.
• May become involved in litigation, arbitration or other proceedings relating to claims arising from the ordinary course of business.

Related Party Transactions

• Biotechnology Value Fund, L.P. (BVF) owned approximately 21.5% of the company's total outstanding common stock as of June 30, 2025. If all Series X Preferred Stock were converted, BVF would own 44.5% of the company's total outstanding common stock. BVF is considered a related party due to its significant equity ownership.

Stakeholder Impact

• Shareholders (Common Stock): Benefit from the stock repurchase program ($2.4 million repurchased in H1 2025) and potential future growth from new acquisitions and maturing royalty streams. Face dilution risk from potential future capital raises.
• Preferred Stockholders (Series A & B): Continue to receive cumulative cash dividends as scheduled.
• Employees: Benefit from stock-based compensation plans (stock options, PSUs, RSUs).
• Partners/Licensees: Continued collaboration and milestone achievements (e.g., Rezolute, Takeda, Affitech, Aptevo).
• Creditors (Blue Owl): Loan principal and interest payments are being made from VABYSMO commercial payments.
• Kinnate CVR Holders: Received modest upfront payments in July 2025 from Kinnate asset sales and are eligible for 85% of net proceeds from future payments.

Next Steps

• Continued deployment of capital towards royalty and acquisition targets.
• Potential future milestone payments to Dar ($11.0 million for each successive $22.0 million received after $88.0 million return threshold).
• Potential sales-based milestone payments that may become due under the agreement with Kuros.
• Payment of $10.0 million contingent consideration to BioInvent upon FDA approval of mezagitamab.
• Evaluation of the impact of the new H.R.1 One Big Beautiful Bill Act on income tax law.
• Closing of the ESSA acquisition by Xeno (facilitated by XOMA).
• Closing of the LAVA acquisition.
• Closing of the HilleVax acquisition.
• Continued semi-annual interest and principal payments on the Blue Owl Loan from VABYSMO commercial payments.
• Potential funding of an additional $0.8 million into the administrative fee escrow account on July 1, 2027.

Key Dates

Recommendation

XOMA Royalty Corporation demonstrates strong operational improvements with significant revenue growth and positive cash flow from operations in the first half of 2025, driven by successful milestone achievements and strategic acquisitions. The company's active portfolio expansion strategy is promising for future income generation. However, the substantial cash outflow for new acquisitions and the continued accumulated deficit indicate that the company is in a growth phase requiring significant investment. While the outlook is positive, the inherent risks associated with biotech royalty aggregation, including reliance on third-party product success and regulatory approvals, suggest a 'hold' recommendation. Investors should monitor the successful integration and commercialization of newly acquired assets and the company's ability to manage its capital deployment effectively.

Keywords

Biotech Royalty Aggregator, SEC Filing, Financial Report, Royalty Payments, Milestone Payments, Biotechnology, Pharmaceuticals, Drug Development, Asset Acquisition, Preferred Stock, SEC 10-Q, XOMA Royalty Corporation, VABYSMO, OJEMDA, IXINITY, ersodetug, mezagitamab, D-Fi, Stock Repurchase